Starting at $160/mo. Defy Medical is one of the providers covered in our editorial directory that dispenses or coordinates FOXO4-DRI.
Read review →FOXO4-DRI
FOXO4-DRI is a synthetic peptide designed to selectively induce apoptosis in senescent cells, a foundational mechanism of biological aging. Heavily studied in mouse models of aging.
FOXO4-DRI is a synthetic peptide designed to selectively induce apoptosis in senescent cells, a foundational mechanism of biological aging. Heavily studied in mouse models of aging. Mechanism: Senolytic peptide. Typical route: Intraperitoneal (animal); SC (human protocols). FDA status: Not FDA-approved. Available through research-chemical suppliers; clinical-grade compounded versions are uncommon. Human safety and efficacy data are essentially nonexistent.
Mechanism of action
FOXO4-DRI disrupts the interaction between FOXO4 and p53 in senescent cells, releasing p53 to trigger apoptosis selectively in cells that have entered senescence. Healthy cells are spared. The result is a 'senolytic' clearance of accumulated senescent cells.
Dosing reference
Animal-protocol dosing: 5 mg/kg intraperitoneal, three doses over five days, repeated every several weeks. Human dosing is not standardized; clinical-trial data is absent.
Dosing information is provided for educational reference and is not medical advice. Patients should not initiate or modify any peptide regimen without consulting a licensed clinician. See our medical disclaimer.
FDA status & regulatory framework
Not FDA-approved. Available through research-chemical suppliers; clinical-grade compounded versions are uncommon. Human safety and efficacy data are essentially nonexistent.
U.S. telehealth providers that work with FOXO4-DRI
Starting at $180/mo. Marek Health is one of the providers covered in our editorial directory that dispenses or coordinates FOXO4-DRI.
Read review →Starting at $199/mo. BreezeMeds is one of the providers covered in our editorial directory that dispenses or coordinates FOXO4-DRI.
Read review →Starting at $149/mo. Hone Health is one of the providers covered in our editorial directory that dispenses or coordinates FOXO4-DRI.
Read review →Related longevity peptides
Frequently asked questions about FOXO4-DRI
Does FOXO4-DRI work in humans?
Human clinical-trial data is essentially absent. Mouse-model results are striking (reduced frailty, restored kidney and coat function) but cross-species extrapolation in senolytics has historically been imperfect.
Is FOXO4-DRI safe?
Long-term safety in humans is unknown. Senolytic mechanisms can theoretically have off-target effects on stem cells. We do not recommend self-experimentation outside of monitored clinical trials.